IT Hardware Assistant

Overview

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary

We are seeking an experienced IT Hardware Assistant for our pre-clinical  facility located in Tranent, just outside of Edinburgh.

 

The successful applicant will work as part of the IT Services team reporting to the IT Site Lead.  Duties will include the configuration, support and routine administration of IT equipment including PC’s, laptops, mobile devices, printers. 

Ideally, you’ll have Highers or equivalent in Computing.  Training will be given where necessary.

This post will involve considerable end-user contact as part of our service delivery, therefore good interpersonal skills and an awareness of our customers’ needs are essential.

 

The following are minimum requirements related to the IT Hardware Assistant position. 

•    Good working knowledge of Windows 7 and Windows 10 operating systems
•    Basic networking knowledge
•    Previous experience of working in a customer support role
•    Good communication skills and customer facing skills
•    Basic knowledge and understanding of Office 365
•    Basic understanding of PC hardware and configuration
•    The ability to work as part of a team or on your own as and when required
•    Must be willing to travel to other sites within Edinburgh

 

All internal applicants should apply through the careers page on Talent Hub.

 

The closing date for this position is Monday, 01 June 2020.

 

About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.

 

About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

With over 14,000 employees within 80 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2018, revenue increased by 22% to $2.27 billion from $1.86 billion in 2017.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2018.